All News
Clinical TrialApril 11, 2026
BTK Inhibitors New Hope for Progressive MS: HERCULES and FENhance Trial Results
Tolebrutinib and Fenebrutinib promise as the first drug class crossing the blood-brain barrier for progressive MS treatment.
BTK inhibitors represent a potential paradigm shift in MS treatment. Unlike most current DMTs targeting peripheral immune system, BTK inhibitors cross the blood-brain barrier to directly target microglia and B cell activation within the CNS.
Tolebrutinib (GEMINI, NEJM 2024) and Fenebrutinib (FENhance, Lancet 2025) show promise especially for progressive MS patients.
Source: NEJM / Lancet / Nature Reviews Neurology